Introduction

Background

The spinal cord tapers and ends at the level between the first and second lumbar vertebrae in an average adult. The most distal bulbous part of the spinal cord is called the conus medullaris, and its tapering end continues as the filum terminale. The upper border of the conus medullaris is often not well defined. Distal to this end of the spinal cord is a collection of nerve roots, which are horsetail-like in appearance and hence called the cauda equina (Latin for horse’s tail). These nerve roots constitute the anatomic connection between the central nervous system (CNS) and the peripheral nervous system (PNS). They are arranged anatomically according to the spinal segments from which they originated and are within the cerebrospinal fluid (CSF) in the subarachnoid space with the dural sac ending at the level of second sacral vertebra.

Pathophysiology

The conus medullaris part of the spinal cord obtains its blood supply primarily from 3 spinal arterial vessels—the anterior median longitudinal arterial trunk and 2 posterolateral trunks. Less prominent sources of blood supply include radicular arterial branches from the aorta, lateral sacral arteries, and the fifth lumbar, iliolumbar, and middle sacral arteries. The latter contribute more to the vascular supply of the cauda equina, although not in a segmental fashion, unlike the blood supply to the peripheral nerves. The nerve roots may also be supplied by diffusion from the surrounding CSF. Moreover, a proximal area of the nerve roots may have a zone of relative hypovascularity.

In understanding the pathological basis of any disease involving the conus medullaris, keep in mind that this structure constitutes part of the spinal cord (the distal part of the cord) and is in proximity to the nerve roots. Thus, injuries to this area often yield a combination of upper motor neuron (UMN) and lower motor neuron (LMN) symptoms and signs in the dermatomes and myotomes of the affected segments. On the other hand, a cauda equina lesion is a LMN lesion because the nerve roots are part of the PNS. Cauda equina and conus medullaris syndromes are classified as clinical syndromes of the spinal cord; epidemiological data on the 2 syndromes are often not available separately from the general data on spinal cord injury.

Frequency
United States
Frequency is determined by the underlying etiology. Multiple conditions can result in a cauda equina or conus medullaris syndrome as outlined later in this article.

Mortality/Morbidity
Morbidity and especially mortality rates are determined by the underlying etiology. Multiple conditions can result in cauda equina or conus medullaris syndrome, as outlined later in this article.

Race
Currently, no published study looks at the incidence of these conditions based on race.

Sex
Currently, no published study looks at the incidence of these conditions based on gender.

Age
Currently, no published study looks at the incidence of these conditions based on age.

Clinical

Table 1. Symptoms and Signs of Conus Medullaris and Cauda Equina Syndromes

<table>
<thead>
<tr>
<th></th>
<th>Conus Medullaris Syndrome</th>
<th>Cauda Equina Syndrome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Presentation</td>
<td>Sudden and bilateral</td>
<td>Gradual and unilateral</td>
</tr>
<tr>
<td>Reflexes</td>
<td>Knee jerks preserved but ankle jerks affected</td>
<td>Both ankle and knee jerks affected</td>
</tr>
<tr>
<td>Radicular pain</td>
<td>Less severe</td>
<td>More severe</td>
</tr>
</tbody>
</table>
Low back pain

More

Less

Numbness tends to be more localized to perianal area; symmetrical and bilateral; sensory dissociation occurs

Numbness tends to be more localized to saddle area; asymmetrical, may be unilateral; no sensory dissociation; loss of sensation in specific dermatomes in lower extremities with numbness and paresthesia; possible numbness in pubic area, including glans penis or clitoris

Sensory symptoms and signs

Typically symmetric, hyperreflexic distal paresis of lower limbs that is less marked; fasciculations may be present

Asymmetric areflexic paraplegia that is more marked; fasciculations rare; atrophy more common

Motor strength

Impotence

Urine retention and atonic anal sphincter cause overflow urinary incontinence and fecal incontinence; tend to present early in course of disease

Urinary retention; tends to present late in course of disease

Frequent

Less frequent; erectile dysfunction that includes inability to have erection, inability to maintain erection, lack of sensation in pubic area (including glans penis or clitoris), and inability to ejaculate

Sphincter dysfunction

Physical

The symptoms described in History are associated with corresponding signs pointing to an LMN or UMN lesion. Refer to Media files 1-2 for assistance in examining the patient and documenting examination findings. In addition to the signs listed below, signs of other possible causes should be sought (eg, examination of the peripheral pulses to rule out possible vascular cause or ischemia of the conus medullaris).

- Signs of cauda equina syndrome include the following:
  - Muscle strength in the lower extremities is diminished. This may be specific to the involved nerve roots as listed below, with the lower lumbar and sacral roots more affected, leading to diminished strength in the glutei muscles, hamstring muscles (ie, semimembranosus, semitendinosus, biceps femoris), and the gastrocnemius and soleus muscles.
  - Sensation is decreased to pinprick and light touch in a dermatomal pattern corresponding to the affected nerve roots. This includes saddle anesthesia (sometimes including the glans penis or clitoris) and decreased sensation in the lower extremities in the distribution of lumbar and sacral nerves. Vibration sense may also be affected. Sensation of the glans penis or clitoris should be examined.
- Muscle stretch reflexes may be absent or diminished in the corresponding nerve roots. Babinski reflex is diminished or absent.
- Bulbocavernous reflexes may be absent or diminished. This should always be tested.
- Anal sphincter tone is patulous and should always be tested since it can define the completeness of the injury (with bulbocavernous reflex); it is also useful in monitoring recovery from the injury.
- Urinary incontinence could also occur secondary to loss of urinary sphincter tone; this may also present initially as urinary retention secondary to a flaccid bladder.
- Muscle tone in the lower extremities is decreased, which is consistent with an LMN lesion.

- Signs of conus medullaris syndrome include the following:
  - Patients may exhibit hypertonicity, especially if the lesion is isolated and primarily UMN.
  - Signs are almost identical to those of the cauda equina syndrome, except that in conus medullaris syndrome signs are more likely to be bilateral; sacral segments occasionally show preserved bulbocavernous reflexes and normal or increased anal sphincter tone; the muscle stretch reflex may be hyperreflexic, especially if the conus medullaris syndrome (ie, UMN lesion) is isolated; Babinski reflex may affect the extensors; and muscle tone might be increased (ie, spasticity).
  - Other signs include papilledema (rare, occurs in lower spinal cord tumors), cutaneous abnormalities (eg, cutaneous angioma, pilonidal sinus that may be present in dermoid or epidermoid tumors), distended bladder due to areflexia, and other spinal abnormalities (noted on lower back examination) predisposing the patient to the syndrome.

- Muscle strength of the following muscles should be tested to determine the level of lesion:
  - L2 - Hip flexors (iliopsoas)
  - L3 - Knee extensors (quadriceps)
  - L4 - Ankle dorsiflexors (tibialis anterior)
  - L5 - Big toe extensors (extensor hallucis longus)
  - S1 - Ankle plantar flexors (gastrocnemius/soleus)

- In defining impairments associated with a spinal cord lesion, the American Spinal Cord Injury Association (ASIA) impairment scale is used in determining the level and extent of injury.
  - This scale should also be used in defining the extent of conus medullaris syndrome/cauda equina syndrome; the scale is as follows:
    - A - Complete; no sensory or motor function preserved in sacral segments S4-S5
    - B - Incomplete; sensory, but not motor, function preserved below the neurologic level and extends through sacral segments S4-S5
C - Incomplete; motor function preserved below the neurologic level, and the majority of key muscles below the neurologic level have a muscle grade less than 3
D - Incomplete; motor function preserved below the neurologic level, and the majority of key muscles below the neurologic level have a muscle grade greater than or equal to 3
E - Normal; sensory and motor function normal

The injury should be described using this scale, for example, ASIA class A. Most patients with cauda equina/conus medullaris syndrome are in ASIA class A or B initially and gradually improve to class C, D, or E. Table 2. Root and Peripheral Nerve Innervation of the Lumbosacral Plexus

<table>
<thead>
<tr>
<th>Muscle</th>
<th>Nerve</th>
<th>Root</th>
</tr>
</thead>
<tbody>
<tr>
<td>Iliopsoas</td>
<td>Femoral</td>
<td>L2, 3, 4</td>
</tr>
<tr>
<td>Adductor longus</td>
<td>Obturator</td>
<td>L2, 3, 4</td>
</tr>
<tr>
<td>Gracilis</td>
<td>Obturator</td>
<td>L2, 3, 4</td>
</tr>
<tr>
<td>Quadriceps femoris</td>
<td>Femoral</td>
<td>L2, 3, 4</td>
</tr>
<tr>
<td>Anterior tibial</td>
<td>Deep peroneal</td>
<td>L4, 5</td>
</tr>
<tr>
<td>Extensor hallucis longus</td>
<td>Deep peroneal</td>
<td>L4, 5</td>
</tr>
<tr>
<td>Extensor digitorum longus</td>
<td>Deep peroneal</td>
<td>L4, 5</td>
</tr>
<tr>
<td>Extensor digitorum brevis</td>
<td>Deep peroneal</td>
<td>L4, 5, S1</td>
</tr>
<tr>
<td>Peroneus longus</td>
<td>Superficial peroneal</td>
<td>L5, S1</td>
</tr>
<tr>
<td>Internal hamstrings</td>
<td>Sciatic</td>
<td>L4, 5, S1</td>
</tr>
<tr>
<td>External hamstrings</td>
<td>Sciatic</td>
<td>L5, S1</td>
</tr>
<tr>
<td>Gluteus medius</td>
<td>Superior gluteal</td>
<td>L4, 5, S1</td>
</tr>
<tr>
<td>Gluteus maximus</td>
<td>Inferior gluteal</td>
<td>L5, S1, 2</td>
</tr>
<tr>
<td>Posterior tibial</td>
<td>Tibial</td>
<td>L5, S1</td>
</tr>
<tr>
<td>Muscle</td>
<td>Nerve</td>
<td>Levels</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-----------</td>
<td>--------</td>
</tr>
<tr>
<td>Flexor digitorum longus</td>
<td>Tibial</td>
<td>L5, S1</td>
</tr>
<tr>
<td>Abductor hallucis brevis</td>
<td>Tibial (medial plantar)</td>
<td>L5, S1, 2</td>
</tr>
<tr>
<td>Abductor digiti quinti pedis</td>
<td>Tibial (lateral plantar)</td>
<td>S1, 2</td>
</tr>
<tr>
<td>Gastrocnemius lateral</td>
<td>Tibial</td>
<td>L5, S1, 2</td>
</tr>
<tr>
<td>Gastrocnemius medial</td>
<td>Tibial</td>
<td>S1, 2</td>
</tr>
<tr>
<td>Soleus</td>
<td>Tibial</td>
<td>S1, 2</td>
</tr>
</tbody>
</table>

**Causes**

The most common causes of cauda equina and conus medullaris syndromes are the following:

- Lumbar stenosis (multilevel)
- Spinal trauma including fractures
- Herniated nucleus pulposus (cause of 2-6% of cases of cauda equina syndrome)
- Neoplasm, including metastases, astrocytoma, neurofibroma, and meningioma: Twenty percent of all spinal tumors affect this area.
- Spinal infection/abscess, such as tuberculosis, herpes simplex virus, meningitis, meningovascular syphilis, cytomegalovirus, or schistosomiasis
- Idiopathic, eg, spinal anesthesia. These syndromes may occur as complications of the procedure or of the anesthetic agent (eg, hyperbaric lidocaine, tetracaine).
- Spina bifida and tethered cord syndrome
- Other, rare causes
  - Spinal hemorrhage, especially subdural and epidural hemorrhage causing compression within the spinal canal
  - Intravascular lymphomatosis
  - Congenital anomalies of the spine/filum terminale including tethered cord syndrome
- Conus medullaris lipomas
- Multiple sclerosis
- Spinal arteriovenous malformations
- Late-stage ankylosing spondylitis
- Neurosarcoïdosis

- Deep venous thrombosis of the spinal veins (propagated)

### Differential Diagnoses

<table>
<thead>
<tr>
<th>Acute Inflammatory Demyelinating Polyradiculoneuropathy</th>
<th>Multiple Sclerosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcohol (Ethanol) Related Neuropathy</td>
<td>Neurosarcoïdosis</td>
</tr>
<tr>
<td>Amyotrophic Lateral Sclerosis</td>
<td>Pathophysiology of Chronic Back Pain</td>
</tr>
<tr>
<td>Chronic Inflammatory Demyelinating Polyradiculoneuropathy</td>
<td>Spinal Cord Hemorrhage</td>
</tr>
<tr>
<td>Dermatomyositis/Polymyositis</td>
<td>Spinal Cord Infarction</td>
</tr>
<tr>
<td>Diabetic Neuropathy</td>
<td>Spinal Cord Trauma and Related Diseases</td>
</tr>
<tr>
<td>Femoral Mononeuropathy</td>
<td>Spinal Epidural Abscess</td>
</tr>
<tr>
<td>HIV-1 Associated Distal Painful Sensorimotor Polyneuropathy</td>
<td>Syringomyelia</td>
</tr>
<tr>
<td>HIV-1 Associated Multiple Mononeuropathies</td>
<td>Traumatic Peripheral Nerve Lesions</td>
</tr>
<tr>
<td>HIV-1 Associated Myopathies</td>
<td>Tropical Myeloneuropathies</td>
</tr>
<tr>
<td>HIV-1 Associated Neuromuscular Complications (Overview)</td>
<td></td>
</tr>
</tbody>
</table>

### Other Problems to Be Considered

- Abdominal aortic aneurysm
- Amyloidosis with deposits in the spinal cord
- Ankylosing spondylitis and other spondyloarthropathy
- Charcot-Marie-Tooth disease (types 1 and 3)
- Guillain-Barré syndrome
- Herniated lumbar or sacral disk
- Intravascular lymphomatosis
Lipomas within the spine
Lumbar stenosis (multilevel)
Neoplasm in the spine
Paget disease of the spine
Peripheral neuropathy and its various causes
Retroperitoneal mass, including neoplasm and hematoma
Sacral plexus injury (eg, after surgery, such as abdominal-perineal resection, sacral excision, or radical hysterectomy)
Spinal infection/abscess and meningitis
Spina bifida/congenital anomalies of the spine/filum terminale
Spinal degenerative diseases
Spinal hemorrhage
Spondylolisthesis
Tethered cord syndrome/short filum terminale
Vascular intermittent claudication
Back pain

**Workup**

**Laboratory Studies**

- These studies may help to define possible causes and any associated pathology, especially other causes of lesions in the lower spinal cord or cauda equina.
  - CBC count, blood glucose, electrolytes, blood urea nitrogen (BUN), and creatinine - As part of the workup to rule out associated anemia, infection, and renal dysfunction, especially in associated retroperitoneal mass
  - Elevated erythrocyte sedimentation rate (ESR) - May point to an inflammatory pathology
  - Syphilitic serology to rule out meningovascular syphilis

**Imaging Studies**

- MRI\(^8\,9\) with contrast of the lumbosacral spine is the diagnostic test of choice and provides a more complete radiographic assessment of the spine than other tests. Gadolinium contrast MRI is currently the most sensitive imaging for detecting intradural neoplasms. It also may be able to rule out abdominal aneurysm, which could be the source of emboli causing conus medullaris infarction. See Media files 3-5 for representative MRIs.

- CT scan\(^10\) myelogram may reveal an intradural or extradural mass or lesions affecting the conus medullaris.
Plain radiographs of the lumbosacral spine are still useful and may depict early changes in vertebral erosions secondary to tumors and spina bifida. Chest radiography is indicated to rule out a pulmonary source of pathology that could affect the lumbosacral spine (e.g., malignant tumor, tuberculosis). Follow-up chest CT may be required.

Bone scan may detect malignant tumor or metastases and inflammatory conditions affecting the vertebrae.

**Other Tests**

- Needle electromyography (EMG)\(^1\) may show evidence of acute denervation, especially in cauda equina lesions and multilevel lumbar spinal stenosis. EMG studies also could help in predicting prognosis and monitoring recovery. Performing needle EMG of the bilateral external anal sphincter muscles is recommended.

- Nerve conduction studies\(^1\)\(^2\) especially of the pudendal nerve, may rule out more distal peripheral nerve lesions.

- Somatosensory evoked potentials (SSEPs)\(^1\)\(^2\) could be done as part of the workup to rule out multiple sclerosis, which could present initially as a lower spinal cord syndrome.

- Duplex ultrasound of peripheral vessels may rule out compromised vasculature as a possible cause of associated claudication.

**Procedures**

Lumbar puncture should be performed to examine the CSF to rule out inflammatory disease of the meninges or spinal cord.

**Treatment**

**Medical Care**

Specific treatment is directed at the primary cause; these are discussed in other articles. As discussed below, the general treatment goals are to minimize the extent of injury and to treat ensuing general complications.

- Acute care: In an acute setting, treatment options entail minimizing possible inflammation and preventing further trauma that might cause worsening of the injury. This is of even greater importance if the cause is trauma.
  - Maintenance of adequate airway, cardiopulmonary resuscitation, fluid management, and initial immobilization (using a molded thoracolumbosacral orthosis) are necessary to limit further damage.
  - Methylprednisolone should be administered as indicated in Medication. This treatment must be started within 8 hours of injury. No evidence exists of any
benefit if it is started more than 8 hours after injury; on the contrary, late treatment may have detrimental effects.

- Administration of GM1 ganglioside sodium salt beginning within 72 hours of injury may be beneficial; the dose is 100 mg IV qd for 18-32 days.
- Tirilazad mesylate (a nonglucocorticoid 21-aminosteroid) has been proven to be of benefit in animals and is currently under investigation. It inhibits lipid peroxidation and hydrolysis in the same manner as glucocorticoids.

- Any specific causal factor should be treated as soon as it has been identified.

- Treatment/prevention of possible complications should begin immediately, including the following:
  - Deep venous thrombosis/pulmonary embolism: Patients should use antiembolic compression stockings and subcutaneous heparin for 3 months as prophylaxis. Low-molecular-weight heparin also has been approved for prophylaxis. Ultrasound of the lower extremities may need to be done as an initial screening test with follow-up later.
  - Neurogenic bladder: Patients may require bladder catheterization.
  - Pressure ulcers: These may be prevented by eliminating pressure, optimizing wound-healing environment, and debriding if necessary.
  - Impotence: Use of sildenafil (Viagra) is becoming popular. Other drugs include yohimbine, papaverine, and alprostadil. Methods to promote coitus and/or ejaculation could also be used; these include implantable penile prostheses or vibrator stimulation.
  - Fecal incontinence: Patients may require use of stool softener or manual evacuation.
  - Heterotopic ossification: Heterotropic ossification (HO) can be confirmed by a triple-bone scan with associated elevated alkaline phosphatase and phosphate, especially in the early stage. Treatment includes stretching exercises, disodium etidronate (20 mg/kg qd x 2 wk, then 10 mg/kg for as long as 12 wk), radiation, and surgical excision. Surgery is done only when the HO has matured or stabilized, which is evident by stable plain x-ray, normal alkaline phosphatase level, and decline in triple-phase bone scan activity.
  - Pain: Pain should be treated appropriately based on its origin; treatment may include narcotics in the acute setting and tricyclic antidepressants later. Patient education, biofeedback, and relaxation techniques may also be used.
  - Spasticity: Use of orthoses is advised to prevent contractures. Use of antispasticity medications also is encouraged. Other medications include dantrolene, diazepam, clonidine, and tizanidine. Nerve blocks also could be done to relieve spasticity; appropriate agents include phenol, botulinum toxin, or local anesthetics.

**Surgical Care**

In acute compression of the conus medullaris or cauda equina, surgical decompression as soon as possible (preferably within 6 h of injury) becomes mandatory. In a more chronic presentation with less severe symptoms, decompression could be performed when medically feasible and should be delayed to optimize the patient's medical condition; with this precaution, decompression is less likely to lead to irreversible neurological damage.
Surgical treatment may be necessary for decompression or tumor removal, especially if the patient presents with acute onset of symptoms. Surgical treatment may include any of the following:
- Laminectomy and instrumentation/fusion for stabilization
- Discectomy

Other surgical care may entail wound care, eg, debridement, skin graft, and skin flap/myocutaneous flap.

Consultations
Consultations to different specialties are needed for acute care and follow-up care.

- Urgent consults for follow-up and advice of the following specialists may be required:
  - Neurosurgery/spinal orthopedics: This consultation should assess the need for urgent surgical spinal decompression. Posterior decompression and stabilization offers at least equivalent neurologic outcomes as nonoperative or anterior approaches and has the additional benefits of surgeon familiarity, shorter hospital stays, earlier rehabilitation, and ease of nursing care.¹
  - Plastic surgery: Plastic surgery may be needed if severe skin breakdowns occur.
  - Rehabilitation: This initial consultation may prevent possible complications, including contractures, and may offer the patient advice on bladder/bowel management, wound management, and the required physical therapy/occupational therapy and assistive devices; this would include follow-up, involvement of social workers, and vocational rehabilitation experts for home adaptation (needed on discharge).
  - Dietitian: A dietitian is needed to advise on optimizing the diet to ensure adequate caloric and protein intake. Patients with these syndromes often have an increase in metabolism associated with the healing process.

Diet
See Consultations.

Activity
The rehabilitation team, especially the spinal cord injury rehabilitation physician and occupational and physical therapists, should be involved as soon as possible.

- This entails setting goals in the rehabilitation unit toward maintaining and improving endurance, with the ability to be independent in activities of daily living on
discharge from the hospital or long-term care facility.

- The rehabilitation goals are to maximize the medical, physical, psychological, educational, vocational, and social function of the patient. This involves the following rehabilitation modalities:
  - **Medical** - Ensure adequate prevention and treatment of possible medical complications already discussed, especially deep venous thrombosis, bladder and bowel problems, and decubitus ulcers.
  - **Physical therapy** - Range of motion and strengthening exercises, sitting balance, transfer training, and tilt table as tolerated (because of tendency to orthostatic hypotension). Tilt table should start at 15 degrees, progressing by 10 degrees every 15 minutes up to about 80 degrees with the necessary precautions. Other activities include wheelchair propulsion training, standing table exercises, functional electrical stimulation for increased muscle tone, use of lower extremity orthoses to aid balance and walking, along with ambulation exercises, family training and community skills, and a home exercise program.
  - **Occupational therapy** - Wheelchair training, especially for advanced wheelchair activities; transfer training; activities of daily living program with assistive devices for dressing, feeding, grooming, bathing, and toileting; motor coordination skills training; shower program; upper extremities training to increase strength for the increased demands of wheelchair propulsion and walking with assistive devices; home evaluation; family training; and a home exercise program.
  - **Orthotic/assistive devices** - May be needed for functional household ambulation and, if possible, community ambulation.
    - This entails prescribing and training in proper use of knee-ankle-foot orthoses (KAFO) with forearm crutches for support; for lower lesions, KAFOs or AFOs with canes or crutches may be needed.
    - In addition to the above, bathtub bench, transfer boards, pressure-relieving seats, and wheelchairs are devices that may be needed. The patient should be assessed for these needs prior to discharge from the acute rehabilitation setting.

**Medication**

The rationale for the medications listed in this section was outlined in Medical Care.

**Corticosteroids**

These agents have anti-inflammatory properties and cause profound and varied metabolic effects. Corticosteroids modify the body's immune response to diverse stimuli.

**Methylprednisolone sodium succinate (Adlone, Medrol, Solu-Medrol)**

Decreases inflammation by suppressing migration of polymorphonuclear leukocytes and reversing increased capillary permeability. This prevents further worsening of injury.

Treatment must be started within 8 h of injury; apparently has no benefit if started > 8 h after injury. Late treatment may have detrimental effects.
**Dosing**

**Adult**
30 mg/kg IV over 15 min followed by a 45-min break, then restart IV infusion at 5.4 mg/kg/h for 23 h; medication must be started within 8 h after injury; starting after 8 h may have detrimental effect

**Pediatric**
0.5-1.7 mg/kg/d or 5-25 mg/m²/d PO/IV/IM divided q6-12h

**Interactions**
Digoxin may increase digitalis toxicity secondary to hypokalemia; estrogens may increase levels; phenobarbital, phenytoin and rifampin may decrease levels (adjust dose); monitor patients for hypokalemia when taking concurrent diuretics

**Contraindications**
Documented hypersensitivity; viral, fungal or tubercular skin infections

**Precautions**

**Pregnancy**
C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

**Precautions**
Hyperglycemia, edema, osteonecrosis, peptic ulcer disease, hypokalemia, osteoporosis, euphoria, psychosis, growth suppression, myopathy, and infections are possible complications of glucocorticoid use

**Anticoagulants**
These agents are taken as prophylaxis for deep venous thrombosis and/or pulmonary embolism.

---

**Heparin**
Augments activity of antithrombin III and prevents conversion of fibrinogen to fibrin. Does not actively lyse but is able to inhibit further thrombogenesis. Prevents re-accumulation of clot after spontaneous fibrinolysis. Administer low dose.
Dosing
Adult
5000 U SC q8-12h

Pediatric
Not established

Interactions
Digoxin, nicotine, tetracycline, and antihistamines may decrease effects; NSAIDs, aspirin, dextran, dipyridamole, and hydroxychloroquine may increase toxicity

Contraindications
Documented hypersensitivity; subacute bacterial endocarditis; active bleeding; history of heparin-induced thrombocytopenia

Precautions
Pregnancy
C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions
In neonates, preservative-free heparin recommended to avoid possible toxicity (gaspig syndrome) by benzyl alcohol, which is used as preservative; caution in severe hypotension and shock

Skeletal muscle relaxants
These agents are thought to work centrally by suppressing conduction at the spinal level.

Baclofen (Lioresal)
May induce hyperpolarization of afferent terminals and inhibit both monosynaptic and polysynaptic reflexes at spinal level.

Dosing
Adult
5 mg PO bid, with gradual increase q3d as tolerated to 30-80 mg qd in divided doses (tid/qid).
Intrathecal: Test dose 50-100 mcg, doses >50 mcg should be given in 25-mcg increments separated by 24h; maintenance: after positive response to test dose, initial dose (via intrathecal pump) is twice test dose, given over 24-h period

**Pediatric**
Generally not recommended for children <12 y for safety reasons.
<12 years: 2.5 to 5 mg PO bid with gradual increase q3d as tolerated
<8 years: Not to exceed 30 mg/d
8-12 years: Not to exceed 60 mg/d
>12 years: Administer as in adults

**Interactions**
Opiate analgesics, benzodiazepines, alcohol, TCAs, guanabenz, MAOIs, clindamycin, and hypertensive agents may increase effects

**Contraindications**
Documented hypersensitivity

**Precautions**

**Pregnancy**
C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

**Precautions**
Caution in patients with history of autonomic dysreflexia and when spasticity is utilized to obtain increased function; autonomic dysreflexia can result from withdrawal of this medication

---

**Dantrolene (Dantrium)**
Stimulates muscle relaxation by modulating skeletal muscle contractions at site beyond myoneural junction and acting directly on muscle itself. Prevents calcium release from sarcoplasmic reticulum.

**Dosing**

**Adult**
Begin with 25 mg PO qd; increase to 25 mg bid/qid, then by 25-mg increments to as high as 100 mg, bid/qid prn

**Pediatric**
Start with 0.5 mg/kg PO bid, increase to 0.5 mg/kg bid/qid, then by increments of 0.5 mg/kg to 3 mg/kg bid/qid prn; not to exceed 100 mg qid

**Interactions**
Toxicity may increase with coadministration of clofibrate and warfarin; coadministration with estrogen may increase hepatotoxicity in women older than 35 y

**Contraindications**
Documented hypersensitivity; active hepatic disease (hepatitis and cirrhosis)

**Precautions**

**Pregnancy**
C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

**Precautions**
May cause hepatotoxicity (use only for recommended indications); caution in impaired pulmonary function and severe cardiac insufficiency; may cause photosensitivity with exposure to sunlight

**Benzodiazepines**
These agents may act in the spinal cord to induce muscle relaxation.

**Diazepam (Diastat, Diazemuls, Valium)**
Depresses all levels of CNS (eg, limbic and reticular formation), possibly by increasing activity of GABA. Individualize dosage and increase cautiously to avoid adverse effects.

**Dosing**

**Adult**
Mild spasms: 5-10 mg PO q4-6h prn
Moderate spasms: 5-10 mg IV prn
Severe spasms: Mix 50-100 mg in 500 mL D5W and infuse at 40 mL/h

**Pediatric**
Mild spasms: 0.1-0.8 mg/kg/d PO divided tid/qid
Moderate or severe spasms: 0.1-0.3 mg/kg IV q4-8h

**Interactions**
Phenothiazines, barbiturates, alcohols, and MAOIs increase CNS toxicity when administered concurrently

**Contraindications**
Documented hypersensitivity; narrow-angle glaucoma

**Precautions**
**Pregnancy**
D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

**Precautions**
Caution with other CNS depressants, low albumin levels, or hepatic disease (may increase toxicity)

**Alpha 2-adrenergic agonist agents**
May reduce sympathetic outflow, which may produce a reduction in muscle tone.

**Clonidine (Catapres)**
Stimulates alpha2-adrenoreceptors in brain stem, activating an inhibitory neuron, which in turn results in reduced sympathetic outflow.

**Dosing**
**Adult**
1 mg PO bid; titrate to effect; not to exceed 2.4 mg/d

**Pediatric**
5-30 mcg/kg/d PO

**Interactions**
Tricyclic antidepressants inhibit hypotensive effects of clonidine; coadministration of clonidine with beta-blockers may potentiate bradycardia; tricyclic antidepressants may enhance hypertensive response associated with abrupt clonidine withdrawal; hypotensive effects of clonidine are enhanced by narcotic analgesics

**Contraindications**
Documented hypersensitivity

**Precautions**
**Pregnancy**
C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

**Precautions**
Caution in cerebrovascular disease, coronary insufficiency, sinus node dysfunction, and renal impairment

**Tizanidine (Zanaflex)**
Centrally acting muscle relaxant metabolized in the liver and excreted in urine and feces.

**Dosing**
**Adult**
4-8 mg PO q8h prn; not to exceed 36 mg/d

**Pediatric**
Not established

**Interactions**
May interact with alcohol (increase somnolence, stupor) and oral contraceptives (which decrease its clearance), and can cause increased hypotensive effects when administered concurrently with diuretics
Contraindications
Documented hypersensitivity

Precautions

Pregnancy
C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions
Caution in renal impairment

Neuromuscular blocker agent, toxin
These agents inhibit transmission of impulses in neuromuscular tissue.

Botulinum Toxin Type A (BOTOX®)
Binds to receptor sites on motor nerve terminals and inhibits release of acetylcholine, which in turn inhibits transmission of impulses in neuromuscular tissue. Most useful for treating spasticity in the gastrocnemius and soleus muscles; less effective in larger muscles such as quadriceps. Re-examine patients 7-14 d after initial dose, to assess for response. May be repeated q3-4mo.

Dosing

Adult
1.25-2.5 U (0.05-0.1 mL) IM injection into most active muscles; give q3-4mo

Pediatric
<12 years: Not established
>12 years: Administer as in adults

Interactions
Aminoglycosides or drugs that interfere with neuromuscular transmission may potentiate effects of botulinum toxin

Contraindications
Documented hypersensitivity

Precautions

Pregnancy
C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions
Do not exceed recommended dosages and frequencies of administration; presence of antibodies to botulinum toxin type A may reduce effects of therapy; when used for cervical dystonia it may cause dysphagia, upper respiratory infection, neck pain, or headache; ptosis may occur when used for blepharism or strabismus
When used cosmetically for glabellar lines may cause headache, respiratory infection, flu syndrome, blepharoptosis, or nausea

Bisphosphonate derivatives
Analogos of pyrophosphate and act by binding to hydroxyapatite in bone-matrix, thereby inhibiting the dissolution of crystals. Prevent osteoclast attachment to the bone matrix and osteoclast recruitment and viability.

Etidronate disodium (Didronel)
Inhibits normal and abnormal bone resorption. Appears to inhibit bone resorption without inhibiting bone formation and mineralization.

Dosing
Adult
20 mg/kg PO qd for 2 wk, then 10 mg/kg for as long as 12 wk

Pediatric
Not established

Interactions
Coadministration with calcium containing products and other multivalent cations decrease absorption

Contraindications
Documented hypersensitivity; hypocalcemia, renal impairment
Precautions

Pregnancy
B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions
Monitor hypercalcemia-related parameters (eg, serum levels of calcium, phosphate, magnesium and potassium); maintain adequate intake of calcium and vitamin D to prevent severe hypocalcemia; caution if active upper GI problems; do not administer with alendronate for osteoporosis in postmenopausal women

Phosphodiesterase (type 5) enzyme inhibitors
These agents increase vasodilatory effects of nitric oxide by inhibiting the enzyme phosphodiesterase type 5, which in turn increases sensitivity for erections.

Sildenafil (Viagra)
Phosphodiesterase type 5 (PDE5) selective inhibitor. Inhibition of PDE5 increases cGMP activity, which increases vasodilatory effects of nitric oxide. Effective in men with mild-to-moderate ED. Take on an empty stomach about 1 h before sexual activity. Sexual stimulation is necessary to activate response. The increased sensitivity for erections may last 24 h. Available as 25-, 50-, and 100-mg tabs.

Dosing
Adult
25-100 mg PO 1 h before sexual activity

Pediatric
Not established

Interactions
Potentiates vasodilatory effect of NO, resulting in potentially fatal drop in blood pressure; coadministration with ketoconazole, erythromycin, or cimetidine increases plasma sildenafil concentrations; coadministration with rifampin decreases plasma levels of sildenafil

Contraindications
Documented hypersensitivity; concurrent or intermittent using of organic nitrates in any form
Precautions

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Adverse effects include headaches (16%), flushing (10%), upset stomach (7%), nasal congestion (4%), and a blue haze at the periphery of vision (3%); adverse effects occur more often in men taking the 100-mg dose; serious adverse effects occur in patients with severe heart disease and those who are taking nitrates; rates of MI were 1.7 and 1.4 per 100 man-years for sildenafil and placebo groups

Vardenafil (Levitra)

Phosphodiesterase type 5 (PDE5) selective inhibitor. Inhibition of PDE5 increases cGMP activity, which increases vasodilatory effects of nitric oxide. Effective in men with mild-to-moderate ED. Take on empty stomach about 1 h before sexual activity. Sexual stimulation is necessary to activate response. Increased sensitivity for erections may last 24 h. Available as 2.5-mg, 5-mg, 10-mg, and 20-mg tabs.

Dosing

Adult

10 mg PO 1 h before sexual activity; may increase to maximum recommended dose of 20 mg or decreased to 5 mg based on efficacy and side effects

Concurrent administration with ritonavir: Not to exceed 2.5 mg PO q72h
Concurrent administration with indinavir, ketoconazole (400 mg PO qd), or itraconazole (400 mg PO qd): Not to exceed 2.5 mg PO q24h
Concurrent administration with ketoconazole (200 mg PO qd), itraconazole (200 mg PO qd), or erythromycin: Not to exceed 5 mg PO q24h

Pediatric

Not established

Interactions

CYP3A4 inhibitors (eg, erythromycin, ketoconazole, itraconazole, indinavir, ritonavir) may significantly increase levels of vardenafil; vardenafil potentiates hypotensive effect of nitrates or alpha-blockers; avoid coadministration with other drugs that prolong QT interval (eg, quinidine, procainamide, amiodarone, sotalol)

Contraindications

Documented hypersensitivity; concurrent or intermittent use of alpha-blockers or organic nitrates in any form
**Precautions**

**Pregnancy**

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

**Precautions**

Common adverse effects include headache, flushing, rhinitis, dyspepsia, or indigestion; assess cardiovascular status before use; caution with left ventricular outflow obstruction or conditions aggravated by hypotension or prolonged QT interval; caution with hepatic impairment (decrease dose); may cause prolonged or painful erection (<2%)

---

**Tadalafil (Cialis)**

Phosphodiesterase type 5 (PDE5) selective inhibitor. Inhibition of PDE5 increases cGMP activity, which increases vasodilatory effects of nitric oxide. Sexual stimulation is necessary to activate response. Increased sensitivity for erections may last 36 h. Available as 5-mg, 10-mg, and 20-mg tabs.

**Dosing**

**Adult**

10 mg PO before sexual activity; may increase to maximum recommended dose of 20 mg or decreased to 5 mg based on efficacy and adverse effects; not to exceed 1 dose per day; may be taken without regard to food

Concurrent administration with potent CYP3A4 inhibitors (eg, ketoconazole, ritonavir): Not to exceed 10 mg PO q72h prn

Moderate renal impairment (CrCl 30-50 mL/min): 5 mg PO qd pm initially; may increase to 10 mg PO q48h pm

Severe renal impairment (CrCl <30 mL/min): Do not exceed 5 mg PO qd pm

Mild-to-moderate hepatic impairment: Do not exceed 10 mg PO qd pm

**Pediatric**

<18 years: Not established

**Interactions**

CYP3A4 inhibitors (eg, erythromycin, ketoconazole, itraconazole, indinavir, ritonavir) may significantly increase levels of vardenafil; vardenafil potentiates hypotensive effect of nitrates or alpha-blockers; concurrent alcohol consumption may increase orthostatic hypotension risk

**Contraindications**
Documented hypersensitivity; concurrent or intermittent use of alpha-blockers (eg, doxazosin, terazosin, prazosin) or organic nitrates in any form

**Precautions**

**Pregnancy**
B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

**Precautions**
Common adverse effects include headache, flushing, rhinitis, dyspepsia, or indigestion; assess cardiovascular status before use; caution with left ventricular outflow obstruction or conditions aggravated by hypotension; caution with hepatic or renal impairment (decrease dose); may cause prolonged or painful erection; may cause back pain or myalgias

**Follow-up**

**Further Inpatient Care**

- Rehabilitation - Physical therapy and occupational therapy for muscle strengthening, endurance, mobility, activities of daily living, gait/balance, use of assistive devices, and adaptation to home environment
- Surgical follow-up for postoperative spinal care, depending on the cause
- Urology⁴ - Cystometrography to define bladder pathology (Patients should undergo regular follow-up on discharge for any renal or bladder complications and impotence, because they have an increased tendency for recurrent urinary tract infection and calculi.)
- Dietitian

**Further Outpatient Care**

- Follow-up with consulting physicians within a week after discharge
- Follow-up with a primary care physician to monitor posthospital medications and other laboratory tests
- Yearly cystoscopy for patients with suprapubic catheters to help detect early bladder malignancies
- Regular follow-up urodynamic studies, renal ultrasound, and general cancer screening
- Follow-up with the rehabilitation team, including the spinal cord injury rehabilitation physician, physical therapist, and occupational therapist. These professionals
are responsible for monitoring community and home integration and following improvements in the patient's strength, coordination, transfer, activities of daily living, and ambulation.

**Inpatient & Outpatient Medications**

This includes continuation of anticoagulation medications (if necessary), antispasticity medications, and other medications being given to ameliorate possible complications, including bladder and bowel problems and heterotopic ossifications. If a patient is on warfarin, one of the team physicians looking after the patient must be designated to monitor the international normalized ratio (INR) at regular intervals.

**Transfer**

On discharge from the surgical ward, patients often are transferred to an acute rehabilitation unit, from which they may be discharged, transferred to a subacute unit, or transferred to long-term care depending on the level of long-term disability.

**Complications**

- Thromboembolic phenomena
- Neurogenic bladder/bowel
- Erectile dysfunction
- Pressure ulcers
- Heterotopic ossification
- Osteoporosis
- Chronic neuropathic pain
- Spasticity/contractures
- Recurrent urinary tract infections
- Urethral stricture
- Bladder calculi
- Depression
Prognosis

- Prognosis can be predicted based on the ASIA impairment scale.
  - ASIA A: Ninety percent of patients remain neurologically complete and unable to have functional ambulation.
  - ASIA B: Seventy-two percent of patients are unable to attain functional ambulation.
  - ASIA C/D: Thirteen percent are unable to attain functional ambulation (reciprocal gait of 200 feet or more) 1 year after injury.

- Ambulatory motor index also is used to predict ambulatory capability, it is calculated using a 4-point scale (0=absent, 1=trace/poor, 2=fair, 3=good or normal) and then calculating hip flexion, hip abduction, hip extension, knee extension, and knee flexion on both sides; the score is expressed as a percentage of the maximum score of 30.
  - A score of 60% or more shows a good chance for community ambulation with no more than one knee-ankle-foot orthosis (KAFO).
  - A patient with a score of 79% or higher may not need an orthosis.
  - A patient with a score of 40% or less may require 2 KAFOs for community ambulation.

Patient Education

- Training in self-catheterization and finger fecal disimpaction, if required
- Use of measures to prevent pressure ulcers, such as skin inspection/care, positioning, turning and transferring tactics, use of skin protectors, or pressure-reducing support surfaces
- Maintenance of endurance and strength-training exercises
- Regular follow-up by the consulting teams who treated the patient in the hospital
- Instructions on how and when medications should be taken and when follow-up laboratory tests should be performed
- For excellent patient education resources, visit eMedicine's Erectile Dysfunction Center and Brain and Nervous System Center. Also, see eMedicine's patient education articles Impotence/Erectile Dysfunction, Erectile Dysfunction FAQs, and Cauda Equina Syndrome.

Miscellaneous

Medicolegal Pitfalls
Physical examination for cauda equina or conus medullaris syndromes would be incomplete without tests for sensation of the saddle and perineal areas, bulbocavernosus reflex, cremasteric reflex, and anal sphincter tone, findings for all of which are likely to be abnormal.

MRI with gadolinium contrast of the lumbosacral area is the diagnostic test of choice to define pathology in the areas of the conus medullaris and cauda equina. Plain x-rays and CT scan may be normal.

Conus medullaris infarction should be considered in the differential diagnosis, and a source of emboli should be sought by ultrasound to rule out an abdominal aortic aneurysm.

HO should be ruled out by triple-bone scan in a patient with pain and swelling of the lower extremity in whom deep venous thrombosis (DVT) has been ruled out. In other words, HO should always be considered as a differential diagnosis of DVT in these patients.

Spinal, metastatic malignant neoplasms should be ruled out and the primary source sought as part of the workup in any patient presenting with any of the symptoms listed in Clinical.
Media file 1: Muscle groups, surface anatomy, peripheral sensory innervation, and dermatomes of the anterior lower limb. This image should be correlated with Tables 1 and 2 in the text. Image courtesy of Nicholas Y. Lorenzo, MD.
Gluteus maximus muscle

Gluteal sulcus

Adductor magnus muscle

Semitendinosus muscle

Long head of the biceps femoris muscle

Tensor fasciae latae muscle

Short head of the biceps femoris muscle

Popliteal fossa

Medial head of the gastrocnemius muscle

Lateral head of the gastrocnemius muscle

Superior cluniar nerves

Medial cluniar nerves

Inferior cluniar nerves

Femoral nerve, anterior cutaneous branch

Obturator nerve, cutaneous branch

Saphenous branch of femoral nerve

L1, L2, L3, L4, L5

L1 sympathetic nerve, lateral cutaneous branch

L2 sympathetic nerve, lateral cutaneous branch

L3 sympathetic nerve, lateral cutaneous branch

L4 sympathetic nerve, lateral cutaneous branch

L5 sympathetic nerve, lateral cutaneous branch

Common fibular nerve, lateral sural cutaneous branch
Media file 2: Muscle groups, surface anatomy, peripheral sensory innervation, and dermatomes of the posterior lower limb. This image should be correlated with Tables 1 and 2 in the text. Image courtesy of Nicholas Y. Lorenzo, MD.
Media file 3: Conus/epiconus infarction in the setting of sickle cell crisis. Image courtesy of Matthew J. Baker, MD.

Media file 4: Conus/epiconus infarction in the setting of sickle cell crisis in the same patient shown in Image 3. Image courtesy of Matthew J. Baker, MD.
Media file 5: Conus/epiconus infarction in the setting of sickle cell crisis in the same patient shown in Images 3 and 4. Image courtesy of
Matthew J. Baker, MD.

References


**Keywords**

lower spinal cord injury, compressive lumbosacral polyradiculopathy, cauda equina syndrome, conus medullaris syndrome, spinal cord compression, back pain, spinal cord injury, upper motor neuron symptoms, UMN symptoms, lower motor neuron symptoms, LMN symptoms, spinal cord syndromes

**Contributor Information and Disclosures**

**Author**

Segun T Dawodu, MD, JD, MBA, FAAPMR, FAANEM, CIME, DipMI(RCSed), Former Clinical Instructor, Mount Sinai Medical School; Current Director, Pain and Injuries Rehabilitation Services, PMRehab Pain and Sports Medicine Associates

Segun T Dawodu, MD, JD, MBA, FAAPMR, FAANEM, CIME, DipMI(RCSed) is a member of the following medical societies: American Academy of Physical Medicine and
Rehabilitation, American Association of Neuromuscular and Electrodiagnostic Medicine, American College of Sports Medicine, American Medical Association, American Medical Informatics Association, Association of Academic Physiatrists, International Society of Physical and Rehabilitation Medicine, and Royal College of Surgeons of England
Disclosure: Nothing to disclose.

Coauthor(s)
Nicholas Y Lorenzo, MD, Chief Editor, eMedicine Neurology; Consulting Staff, Neurology Specialists and Consultants
Nicholas Y Lorenzo, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Neurology
Disclosure: Nothing to disclose.

Medical Editor
Milind J Kothari, DO, Professor and Vice-Chair, Department of Neurology, Pennsylvania State University College of Medicine; Consulting Staff, Department of Neurology, Hershey Medical Center
Milind J Kothari, DO is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Neurological Association
Disclosure: Nothing to disclose.

Pharmacy Editor
Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor
James H Halsey, MD, Professor, Department of Neurology, University of Alabama Medical Center
James H Halsey, MD is a member of the following medical societies: American Academy of Neurology, American Heart Association, American Medical Association, American Neurological Association, American Society of Neuroimaging, Medical Association of the State of Alabama, New York Academy of Sciences, Pan American Medical Association, Sigma Xi, Society for Neuroscience, and Southern Medical Association
Disclosure: Nothing to disclose.

CME Editor
Selim R Benbadis, MD, Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, University of South Florida School of Medicine, Tampa General Hospital
Selim R Benbadis, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Sleep Medicine, American Clinical
Neurophysiology Society, American Epilepsy Society, and American Medical Association
Disclosure: Nothing to disclose.

**Chief Editor**

**Nicholas Y Lorenzo, MD,** Chief Editor, eMedicine Neurology; Consulting Staff, Neurology Specialists and Consultants
Nicholas Y Lorenzo, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Neurology
Disclosure: Nothing to disclose.

**Further Reading**
All Rights Reserved